It has been found that the infection-mimicking polyglutamic acid, at 5 kDa, can be successfully used as an immunoadjuvant to effectively elicit an anti-tumour immune response in a dose-dependent manner, with stimulation of toll-like receptor 4 having been suggested as a mechanism (Seth et al. 2015). This evidence concerns the gene TLR4 and neoplasm.